22nd Century Group (XXII) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
7 May, 2026Executive summary
Q1 2026 focused on execution and growth, with commercial expansion of proprietary VLN® reduced nicotine products now in over 2,000 stores across 20 states, aiming for 5,000 outlets by year-end 2026.
VLN is positioned as a disruptive, FDA-authorized low-nicotine cigarette targeting adult smokers seeking to reduce nicotine dependence, supporting FDA low nicotine initiatives and offering licensing to other tobacco companies.
Net revenues for Q1 2026 were $4.1 million, up from $3.5 million in Q4 2025 but down 31.1% year-over-year due to a strategic shift away from low-priced contract manufacturing customers.
Marketing investments and new leadership in consumer marketing are underway to drive awareness and adoption.
As of March 31, 2026, cash and cash equivalents totaled $9.5 million, and working capital was $13.2 million.
Financial highlights
Net revenue for Q1 2026 was $4.1 million, up 16.1% sequentially from Q4 2025, but down from $6.0 million in Q1 2025.
Gross loss improved to $0.6 million from $0.8 million in Q4 2025, but was slightly higher than $0.6 million in Q1 2025, with a gross margin of -15.5%.
Operating loss was $3 million, compared to $2.8 million in the previous quarter and $2.6 million in Q1 2025.
Net loss from continuing operations was $3 million, with a basic and diluted loss per share of $5.07.
Adjusted EBITDA was negative $2.6 million, compared to negative $2.4 million in Q4 2025.
Outlook and guidance
Targeting distribution in over 5,000 retail outlets by year-end 2026, with new markets in NY, NJ, Southern California, and the Southeast.
Anticipates stronger commercial momentum and improved gross profits in the second half of 2026, prioritizing disciplined cost management and advancing toward EBITDA breakeven.
Management expresses substantial doubt about the ability to continue as a going concern through one year from the financial statement issuance date, citing ongoing losses and negative cash flows.
Latest events from 22nd Century Group
- Proxy seeks director election, executive pay approval, auditor ratification, and highlights growth strategy.XXII
Proxy filing29 Apr 2026 - Shelf registration enables up to $250M in offerings; $1.84M at-the-market sale supports VLN growth.XXII
Registration filing31 Mar 2026 - Net loss narrowed, debt eliminated, and VLN® distribution expanded for growth.XXII
Q4 202526 Mar 2026 - Revenue grew, losses narrowed, but going concern risk persists as VLN rebranding continues.XXII
Q2 20241 Feb 2026 - Low-nicotine cigarettes gain retail traction, targeting break-even and growth with no direct rivals.XXII
17th Annual LD Micro Main Event Conference17 Jan 2026 - Q3 2024 revenue dropped 24.5% with ongoing losses, but net debt and cost structure improved.XXII
Q3 202414 Jan 2026 - Key votes include a reverse split, preferred stock, warrant changes, and a new offering.XXII
Proxy Filing30 Dec 2025 - VLN relaunch, FDA compliance, and CMO focus drive 2025 growth after 2024 turnaround.XXII
Q4 202426 Dec 2025 - Relaunching low-nicotine brands, expanding retail reach, and targeting profitability by Q4 2025.XXII
Emerging Growth Conference26 Dec 2025